SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms

CNS Drug Reviews

Volumn 9, Issue 1, 2003, Pages 3-20

  Griebel, Guy ^a   Perrault, Ghislaine ^a   Simiand, Jacques ^a   Cohen, Caroline ^a   Granger, Patrick ^a   Depoortere, Henri ^a   Françon, Dominique ^a   Avenet, Patrick ^a   Schoemaker, Hans ^a   Evanno, Yannick ^a   Sevrin, Mireille ^a   George, Pascal ^a   Scatton, Bemard ^a  

^a SANOFI   (France)

Author keywords

Anxiety; Anxiolytic; Benzodiazepine; Diazepam; GABAA receptor; Muscle spasm; SL651498

Indexed keywords

1H PYRIDO[3,4 B]INDOLE 4 CARBOXAMIDE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; 6 FLUORO 9 METHYL 2 PHENYL 4 (PYRROLIDIN 1YLCARBONYL) 2,9 DIHYDRO 1H PYRIDO[3,4 B]INDOL 1 ONE; ALCOHOL; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CHLORIDE CHANNEL; DIAZEPAM; FLUMAZENIL; ISONIAZID; RECEPTOR SUBTYPE; TETRAZEPAM; TIZANIDINE; UNCLASSIFIED DRUG; 6 FLUORO 9 METHYL 2 PHENYL 4 (PYRROLIDIN 1 YL CARBONYL) 2,9 DIHYDRO 1H PYRIDO(3,4 B)INDOL 1 ONE; 6-FLUORO-9-METHYL-2-PHENYL-4-(PYRROLIDIN-1-YL-CARBONYL)-2,9-DIHYDRO-1H-PYRIDO(3,4-B)INDOL-1-ONE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTEROGRADE AMNESIA; ANTICONVULSANT ACTIVITY; ATAXIA; CHLORIDE CURRENT; CLONIC SEIZURE; COGNITIVE DEFECT; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERANCE; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; GRIP STRENGTH; HUMAN; HUMAN CELL; MAZE TEST; MINIMAL EFFECTIVE DOSE; MOTOR DYSFUNCTION; MOUSE; MUSCLE RELAXATION; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NONHUMAN; POLYSYNAPTIC REFLEX; RAT; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; REVIEW; SEDATION; TRANQUILIZING ACTIVITY; WITHDRAWAL SYNDROME; ADDICTION; ANIMAL; ANXIETY DISORDER; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISCRIMINATION LEARNING; DRUG EFFECT; DRUG INTERACTION; PERCEPTIVE DISCRIMINATION;

AMNESIA, ANTEROGRADE; ANIMALS; ANXIETY DISORDERS; ATAXIA; CENTRAL NERVOUS SYSTEM; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DRUG INTERACTIONS; DRUG TOLERANCE; ETHANOL; GABA AGONISTS; INDOLES; MICE; PYRROLES; RATS; RECEPTORS, GABA-A; SPASM; SUBSTANCE-RELATED DISORDERS;

EID: 0037358312     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2003.tb00241.x     Document Type: Review

References (62)

1. Barnard EA, Skolnick P, Olsen RW, et al. International Union of Pharmacology. XV. Subtypes of γ-aminobutyric acid A receptors: Classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998;50:291-313.
2. Belzung C, Leguisquet AM, Griebel G. β-CCT, a selective BZ-ω1 receptor antagonist, blocks the anti-anxiety but not the amnesic action of chlordiazepoxide in mice. Behav Pharmacol 2000;11:125-131.
3. Blanchard RJ, Blanchard DC. Anti-predator defense as models of animal fear and anxiety. In: Brain PF, Parmigiani S, Blanchard RJ, Mainardi D, eds. Fear and Defence. London, UK: Harwood Academic Publishers, 1990;89-108.
4. Boissier JR, Simon P, Aron C. A new method for the rapid screening of minor tranquillisers in mice. Eur J Pharmacol 1968;4:145-151.
5. 3H]diazepam binding. Proc Natl Acad Sci USA 1977;74:3805-3809.
6. Cole SO. Effects of benzodiazepines on acquisition and performance: A critical assessment. Neurosci Biobehav Rev 1986;10:265-272.
7. Colpaert FC, Niemegeers CJ, Janssen PA. Theoretical and methodological considerations on drug discrimination learning. Psychopharmacologia 1976;46:169-177.
8. Cooper SJ, Kirkham TC, Estall LB. Pyrazoloquinolines: Second generation benzodiazepine receptor ligands have heterogeneous effects. Trends Pharmacol Sci 1987;3:180-184.
9. Crestani F, Martin JR, Möhler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000;131:1251-1254.
10. Davis M, Falls WA, Campeau S, Kim M. Fear-potentiated startle: A neural and pharmacological analysis. Behav Brain Res 1993;58:175-198.
11. Depoortere H, Zivkovic B, Lloyd KG, et al. Zolpidem, a novel non-benzodiazepine hypnotic: I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 1986;237:649-658.
12. Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficits in rats and mice. J Am Pharm Assoc 1957;46:208-209.
13. Evanno Y, Sevrin M, Maloizel C, Le Galloudec O, George P. 1H-pyrido[3,4-b]indole-4-carboxamide derivatives, preparation and application thereof in therapeutics. WO9815552 1997.
14. A receptor subunits revealed by antigen-retrieval immunohistochemistry. J Comp Neurol 1998;390:194-210.
15. A receptors. J Pharmacol Exp Ther 1993;266:1018-1028.
16. Griebel G, Blanchard DC, Jung A, Blanchard RJ. A model of 'antipredator' defense in Swiss-Webster mice: Effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 1995;6:732-745.
17. Griebel G, Perrault G, Letang V, et al. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ(ω) receptor subtypes. Psychopharmacology 1999;146:205-213.
18. Griebel G, Perrault G, Sanger DJ. Subtype-selective benzodiazepine receptor ligands. In: Briley M, Nutt D, eds. Anxiolytics. Basel: Birkhäuser, 2000;77-94.
19. A) receptors. J Pharmacol Exp Ther 2001;298:753-768.
20. Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ. Comparison of the pharmacological properties of classical and novel BZ-ω receptor ligands. Behav Pharmacol 1999;10:483-495.
21. Haefely W, Martin JR, Schoch P. Novel anxiolytics that acts as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 1990;11:452-456.
22. Haug T, Gotestam KG. Onset and offset of the diazepam stimulus complex. Pharmacol Biochem Behav 1982;17:1171-1174.
23. Hutchinson MA, Smith PF, Darlington CL. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Prog Neurobiol 1996;49:73-97.
24. Irwin S, Kalsner S, Curtis A, Banuazizi A. Direct demonstration of consolidation of one-trial learning. Fed Proc 1964;23:102.
25. Jenser. RA, Martinez JL, Vasquez BJ, McGaugh JL. Benzodiazepines alter acquisition and retention of an inhibitory avoidance response in mice. Psychopharmacology 1979;64:125-126.
26. Lader M. Benzodiazepines: A risk-benefit profile. CNS Drugs 1994;1:377-387.
27. Lecci A, Borsini F, Volterra G, Meli A. Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology 1990;101:255-261.
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25.
29. Lister RG, Linnoila M. Alcohol, the chloride ionophore and endogenous ligands for benzodiazepine receptors. Neuropharmacology 1991;30:1435-1440.
30. Löscher W, Frey HH. Effect of convulsant and anticonvulsant agents on level and metabolism of gammaaminobutyric acid in mouse brain. Naunyn-Schmiedebeig's Arch Pharmacol 1977;296:263-269.
31. Low K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;290:131-134.
32. Mao CC, Guidotti A, Costa E. Evidence for an involvement of GABA in the mediation of the cerebellar CGMP decrease and the anticonvulsant action diazepam. Arch Pharmacol 1975;289:369-378.
33. Martin JR, Pieri L, Bonetti EP, et al. Ro 16-6028: A novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 1988;21:360-362.
34. 1 subtype. Nat Neurosci 2000;3:587-592.
35. Meyer OA, Tilson HA, Byrd WC, Riley MT. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1979;1:233-236.
36. Misslin R, Belzung C, Vogel E. Behavioural validation of a light/dark choice procedure for testing antianxiety agents. Behav Process 1989;8:119-132.
37. Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. JPharmacol Exp Ther 2002;300:2-8.
38. Möhler H, Okada T. Benzodiazepine receptor: Demonstration in the central nervous system. Science 1977;198:849-851.
39. Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982;297:681-683.
40. A receptor alpha subunits after flurazepam treatment. Eur J Pharmacol 1992;226:335-341.
41. Parsons AM, Honda CN, Jia YP, et al. Spinal NK1 receptors contribute to the increased excitability of the nociceptive flexor reflex during persistent peripheral inflammation. Brain Res 1996;739:263-275.
42. Pellow S, Chopin P, File SE, Briley M. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 1985;14:149-167.
43. Perrault G, Morel E, Sanger DJ, Zivkovic B. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics. Eur J Pharmacol 1990;187:487-494.
44. Perrault G, Morel E, Sanger DJ, Zivkovic B. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 1992;263:298-303.
45. Perrault G, Morel E, Sanger DJ, Zivkovic B. Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence. Neuropharmacology 1993;32:855-863.
46. Puia G, Ducic I, Vicini S, Costa E. Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma-aminobutyric acid type A receptor. Proc Natl Acad Sci USA 1992;89:3620-3624.
47. Rothblat LA, Kromer LF. Object recognition memory in the rat: The role of the hippocampus. Behav Brain Res 1991;42:25-32.
48. Rowlett JK, Tomatzky W, Cook JM, Ma CR, Miczek KA. Zolpidem, triazolam, and diazepam decrease distress vocalizations in mouse pups: Differential antagonism by flumazenil and β-carboline-3-carboxylate-tbutyl ester (β-CCt). J Pharmacol Exp Ther 2001;297:247-253.
49. A receptor subtypes. Nature 1999;401:796-800.
50. Sanger DJ. The behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: Increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol 1995;6:116-126.
51. Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994;18:355-372.
52. A receptors: Differential profiles and receptor selectivity. Pharmacol Biochem Behav 1999;64:269-273.
53. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 1996;313:35-42.
54. Schouenborg J, Kalliomaki J. Functional organization of the nociceptive withdrawal reflexes. I. Activation of hindlimb muscles in the rat. Exp Brain Res 1990;83:67-78.
55. Thiebot MH. Some evidence for amnesic-like effects of benzodiazepines in animals. Neurosci Biobehav Rev 1985;9:95-100.
56. A receptor subtype. Proc Natl Acad Sci USA 2001;98:6464-6469.
57. Viana MB, Tomaz C, Graeff FG. The elevated T-maze: A new animal model of anxiety and memory. Pharmacol Biochem Behav 1994;49:549-554.
58. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 1971;21:1-7.
59. Von Voigtlander PF, Lewis RA. A rapid screening method for the assessment of benzodiazepine receptorrelated physical dependence in mice. Evaluation of benzodiazepine-related agonists and partial agonists. J Pharmacol Meth 1991;26:1-5.
60. Wafford KA, Whiting PJ, Kemp JA. Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant γ-aminobutyric acid receptor subtypes. Mol Pharmacol 1993;43:240-244.
61. Woods JH, Winger G. Current benzodiazepine issues. Psychopharmacology 1995;118:107-115.
62. Yasumatsu H, Morimoto Y, Yamamoto Y, et al. The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. Br J Pharmacol 1994;111:1170-1178.